Sevelamer

Summary

Sevelamer (CHEMBL5314349) is an approved small molecule (ATC V03AE02); indicated across 4 conditions including chronic kidney disease and hyperphosphatemia.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: V03AE02
• Indications: 4 conditions
• Clinical trials: 22

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5314349
Name	Sevelamer
Type	Small molecule
Max phase	4
ATC	V03AE02

Also known as: Sevelamer, Sevelamer anhydrous, Sevelamero, sevelamer, SEVELAMER

Parent form; salt/anhydrous children: CHEMBL5314347

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
chronic kidney disease	3	MONDO:0005300	EFO:0003884
hyperphosphatemia	1	MONDO:0000328	MONDO:0000328

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 22.

Phase distribution

Phase	Trials
Not specified	8
PHASE3	5
PHASE2	4
PHASE4	3
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06660524	PHASE4	RECRUITING	Calcium-Phosphorus Regulation Therapy on Heart Valve Disease
NCT00211939	PHASE4	COMPLETED	CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients
NCT01135615	PHASE4	COMPLETED	Sevelamer, FGF-23 and Endothelial Dysfunction in Chronic Kidney Disease (CKD)
NCT00196755	PHASE3	COMPLETED	Study of Safety and Efficacy of Renagel® Compared With Calcium Acetate in Patients With Peritoneal Dialysis
NCT00267514	PHASE3	COMPLETED	Study to Demonstrate Equivalence of Sevelamer Carbonate Powder and Sevelamer HCl Tablets in Haemodialysis Patients
NCT00268957	PHASE3	COMPLETED	Study to Compare Sevelamer Carbonate Powder to Sevelamer Hydrochloride Tablets in Patients With CKD on Hemodialysis
NCT01011699	PHASE3	TERMINATED	Nicotinamide Versus Sevelamer Hydrochloride on Phosphatemia Control on Chronic Hemodialysed Patients
NCT02199444	PHASE3	UNKNOWN	Effect of Sevelamer on P-cresol Levels in CKD
NCT00440648	PHASE2	COMPLETED	Cross-Over Study of Sevelamer Hydrochloride and Sevelamer Carbonate
NCT01968759	PHASE2	COMPLETED	Sevelamer in Proteinuric CKD
NCT02124759	PHASE2	COMPLETED	Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim 1)
NCT02127125	PHASE2	COMPLETED	Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim2)
NCT00875017	PHASE1	COMPLETED	Comparing Absorption of Dietary Phosphorus When Administering FOSRENOL® or RENVELA® in Healthy Adult Volunteers
NCT03305471	PHASE1	COMPLETED	DS2330b Alone and With Sevelamer in Patients on Chronic Hemodialysis
NCT00018135	Not specified	COMPLETED	Parathyroid Hormone Levels in Relation to the Phosphorus Content of Meals
NCT00364000	Not specified	WITHDRAWN	Arterial Stiffness and Calcifications in Haemodialysis Patients on Sevelamer or Calcium Acetate
NCT00710788	Not specified	COMPLETED	Reduce Cardiovascular Calcifications to Reduce QT Interval in Dialysis
NCT00837655	Not specified	WITHDRAWN	Effect of Sevelamer on Glucose Tolerance and Insulin Sensitivity in Patients With Chronic Renal Failure (CKD)
NCT01057186	Not specified	UNKNOWN	Hypophosphatemic Rickets in Norway
NCT02445508	Not specified	COMPLETED	Effect of Bile Acid Secretion and Sequestration on GLP-1 Secretion
NCT02822131	Not specified	COMPLETED	Phosphate in Blood Pressure Regulation
NCT03739268	Not specified	COMPLETED	GLP-1-mediated Gluco-metabolic Effects of Bile Acid Sequestration

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).